Overview

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.
Phase:
Phase 2
Details
Lead Sponsor:
Zhang Lei
Treatments:
Zanubrutinib